Muhammed Majeed, PhD, founder and chairman, Sami-Sabinsa Group published "Boswellin®- Anti-Inflammatory Adaptogen from Nature," the fourth book in a series on derivatives of Boswellia serrata,
Dr. Muhammed Majeed. Image courtesy of Sabinsa Corp.
Muhammed Majeed, PhD, founder and chairman, Sami-Sabinsa Group (East Windsor, NJ) published "Boswellin®- Anti-Inflammatory Adaptogen from Nature," the fourth book in a series on derivatives of Boswellia serrata, edited by Majeed and N. Kalyanam, PhD, and written by other senior scientists of Sami-Sabinsa Group.
“With many botanicals, there is so much more to study than the primarily-known active constituents,” Majeed said in press release. “In studying boswellia, we’ve made some intriguing discoveries about the immunomodulatory polysaccharides of boswellia gum and are eager to share those more widely.”
The book explores the science on boswellic acids and breaks new ground by delving into the long-ignored polysaccharide component of boswellia gum. Boswellic acids are obtained from the gum resin of Boswellia serrata tree. The gum resin exudate of Boswellia serrata has been in use in Ayurvedic system of medicine for the management of rheumatism, respiratory diseases, and liver disorders. The primary use of Boswellia serrata in contemporary medicine is as an anti-arthritic and anti-inflammatory pharmacological agent.
Judge in CRN’s complaint against NY denies the State’s motion to dismiss
May 14th 2024New York State's motion to dismiss CRN's lawsuit against the law banning the sale of weight management and muscle-building supplements to minors has been partially denied, allowing CRN to proceed with its First Amendment Claim.